Wegovy vs Saxenda vs Ozempic: A Three-Way Comparison (May 2026)

Wegovy, Saxenda, and Ozempic are all GLP-1 receptor agonist injections made by Novo Nordisk. If you have heard of all three and want to know which one is right for weight loss — or why your prescriber mentioned a specific one — the answer comes down to three things: what molecule is in the drug, what the FDA has approved it for, and whether insurance will pay.

This comparison covers all three drugs side by side: active ingredients, dosing, FDA indication, real-world efficacy, side effect profile, cash-pay cost, and who each is genuinely best for as of May 2026.

The molecules: two drugs, three brand names

Two GLP-1 molecules are at work across these three products.

Semaglutide is the active ingredient in both Wegovy and Ozempic. It was developed as a structural modification of liraglutide, with changes that increase albumin binding and extend the half-life to approximately 168 hours — enabling once-weekly dosing. For a deeper look at the chemistry, see liraglutide vs semaglutide.

Liraglutide is the active ingredient in Saxenda. It has a half-life of approximately 13 hours, which is why it requires daily injection. Saxenda is the obesity-dose version (3 mg); Victoza (1.8 mg) is the T2D version of the same molecule.

Semaglutide's structural modifications produce both a longer duration of action and higher GLP-1 receptor affinity compared to liraglutide. These properties translate directly into greater central satiety signalling and, in trials, greater weight loss.

At-a-glance comparison

FDA indications: why they matter

The FDA indication shapes everything — insurance coverage, prescriber willingness, and legal liability.

Wegovy is the only drug of the three with an FDA approval specifically for chronic weight management in adults. The approved criteria are: BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidaemia). Wegovy is also the first obesity medication to receive an FDA-approved cardiovascular risk-reduction indication (the SELECT trial showed a 20% reduction in major adverse cardiovascular events in patients with established CVD but without diabetes).

Ozempic is FDA-approved for type 2 diabetes — specifically for A1c reduction and cardiovascular risk reduction in adults with T2D and established CVD. Using Ozempic for weight loss in a patient without T2D is off-label prescribing. That is legal and common, but it means the FDA did not review and approve that specific use.

Saxenda is FDA-approved for the same obesity indication as Wegovy — BMI ≥ 30 or ≥ 27 with comorbidity. The indication is the same; the efficacy is substantially lower.

For patients with both T2D and obesity, any of the three could be clinically relevant. For patients whose primary goal is weight loss without T2D, Wegovy is the only drug of the three that is on-label for that purpose.

Weight loss efficacy: the numbers

This is where the comparison is clearest.

Wegovy (semaglutide 2.4 mg): The STEP 1 trial (published in the New England Journal of Medicine, 2021) enrolled 1,961 adults with obesity but without T2D. At 68 weeks on semaglutide 2.4 mg weekly, mean body weight loss was 14.9–17.4%. About 69% of participants lost at least 10% of body weight. With Wegovy HD (7.2 mg, approved March 2026), the STEP UP trial showed approximately 19% mean weight loss.

Ozempic (semaglutide 1–2 mg): Ozempic's weight data comes primarily from the SUSTAIN trials in T2D populations, where weight loss was a secondary endpoint. Mean weight loss at the 2 mg dose was approximately 8–12%. The lower numbers partly reflect the lower dose ceiling and partly reflect the T2D population's different metabolic baseline. Head-to-head comparisons against Wegovy at 2.4 mg consistently show Wegovy's advantage.

Saxenda (liraglutide 3 mg): The SCALE Obesity trial (56 weeks) showed approximately 8–9% mean weight loss. The STEP 8 head-to-head trial directly compared semaglutide 2.4 mg against liraglutide 3 mg over 68 weeks: semaglutide 2.4 mg produced 15.8% mean loss versus 6.4% for liraglutide — a more than 2:1 difference at the same time point. Saxenda's efficacy is not in dispute; it is simply outperformed by the semaglutide-based drugs.

Dosing and injection frequency

Saxenda's 365 injections per year versus 52 for either semaglutide option is a meaningful adherence burden. This is one of the practical arguments against Saxenda independent of efficacy.

Both Wegovy and Ozempic use a prefilled pen injector. Saxenda also uses a prefilled pen. All three are subcutaneous injections (abdomen, thigh, or upper arm).

Side effects: what differs and what doesn't

All three drugs share the same core GI side effect profile: nausea, vomiting, diarrhoea, and constipation. These are front-loaded at dose increases and typically settle over several weeks at each step. The class-level black-box warning — personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 — applies to all three.

Differences that exist:

Onset of side effects: Saxenda's shorter half-life means levels rise and fall each day. This can produce more day-to-day variation in nausea compared to the more stable weekly peak-trough of semaglutide. Some patients find the predictable weekly injection of semaglutide easier to manage around their schedule.

Injection-site reactions: Comparable across the three.

Severity: The clinical trials show broadly similar GI adverse event rates across the semaglutide and liraglutide products. Individual tolerability varies — some patients who cannot tolerate one molecule tolerate another.

For a detailed guide to managing GI side effects across GLP-1 drugs, see GLP-1 side effects management.

Cost without insurance

As of May 2026:

• Wegovy: NovoCare $349/month flat rate for eligible patients, regardless of dose step. This is the most important number in the cash-pay analysis. See Wegovy without insurance for how to access this pricing.
• Ozempic: Retail approximately $900–1,000/month. The Novo Nordisk savings program can reduce this for commercially insured patients; for truly cash-pay patients without insurance, the savings are more limited. Off-label Ozempic at cash-pay rates is typically more expensive than Wegovy via NovoCare.
• Saxenda: Retail approximately $1,200–1,350/month. Saxenda is the most expensive of the three on a cash-pay basis and the least effective — making it a difficult choice when Wegovy is available at $349/month.

The NovoCare $349 Wegovy flat rate fundamentally changes the cash-pay calculus. It makes Ozempic off-label a less attractive workaround for cash-pay patients than it was in 2022–2023 when Wegovy was $1,300+ without a savings program.

Who each drug is best for

Wegovy is the correct drug for most weight-loss patients who have access to it. The indication is on-label for obesity and overweight-with-comorbidity, the efficacy is highest of the three, the dosing is once weekly, and the NovoCare price makes it accessible without insurance. For patients with established cardiovascular disease and obesity (without T2D), Wegovy is also the only drug of the three with an approved CV risk-reduction indication for that specific population.

Ozempic makes sense when: (1) the patient has type 2 diabetes and insurance covers Ozempic for the T2D indication; (2) the prescriber wants the T2D-approved label with cardiovascular data in a T2D + CVD patient; (3) the patient has a specific clinical reason to stay at or below 2 mg semaglutide. For patients without T2D using Ozempic off-label at cash-pay, Wegovy via NovoCare is usually the better choice on both efficacy and cost grounds. For more on this specific comparison, see Ozempic vs Wegovy.

Saxenda makes sense when: (1) insurance covers Saxenda but not Wegovy or any semaglutide product; (2) the patient cannot tolerate semaglutide and liraglutide is being tried as an alternative; (3) a bridge is needed during a Wegovy prior-authorisation appeal. For any patient with unrestricted access, Saxenda is not the first-line choice. For the direct Saxenda vs Wegovy analysis, see Saxenda vs Wegovy.

The practical bottom line

These three drugs are not equivalent options at the same rung. They represent a hierarchy shaped by molecular generation, approved indication, dosing convenience, and clinical efficacy.

Wegovy is the current-generation, on-label, once-weekly, highest-efficacy option for weight management. Ozempic is the diabetes-approved workaround that many patients end up on for cost or insurance reasons — a workaround that made more sense before NovoCare dropped Wegovy to $349/month. Saxenda is the older daily drug that remains on the market but has been largely superseded in clinical practice.

For patients who want to compare the GLP-1 class against the newer dual-agonist drugs, the next comparison to read is Wegovy vs Mounjaro or tirzepatide vs semaglutide.